KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference

Company Overview - KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on innovative therapies for rare and severe eye diseases [3] - The company utilizes a proprietary mesenchymal stem cell secretome (MSC-S) platform for its biologics-based investigational therapies [3] Product Development - KALA's lead product candidate, KPI-012, is designed to address persistent corneal epithelial defect (PCED), a rare disease linked to impaired corneal healing [3] - KPI-012 has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration [3] - The company is also exploring KPI-012 for Limbal Stem Cell Deficiency and other rare corneal diseases that threaten vision [3] - Preclinical studies are underway to evaluate the MSC-S platform's potential for treating retinal degenerative diseases, including Retinitis Pigmentosa and Stargardt Disease [3] Upcoming Events - Kim Brazzell, Ph.D., Head of R&D and Chief Medical Officer, will present at the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024 [1] - Management will be available for one-on-one meetings on the same day [1]